Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus.
De Pità
O
O
Bellucci
A M
AM
Ruffelli
M
M
Girardelli
C R
CR
Puddu
P
P
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D003176:Complement C3 / Q000032:analysis; D004247:DNA / Q000032:analysis; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D012867:Skin / Q000276:immunology / Q000473:pathology*; D017211:Treatment Failure
D000974:Antibodies, Antinuclear; D003176:Complement C3; D016756:Immunoglobulins, Intravenous; D004247:DNA